Article Sidebar

pdf
Date Published: 05/05/2024
Abstract Views: 126
Views pdf: 64
DOI: https://doi.org/10.51298/vmj.v538i1.9343
Issue
Vol. 538 No. 1 (2024)
Section
Các bài báo
How to Cite
Lương, B. A., Dương, B. T., & Hoàng, A. V. (2024). ESTABLISHMENT OF THE DETECTION OF TERT PROMOTER MUTATIONS IN GLIOMAS BY USING ASO-PCR. Vietnam Medical Journal, 538(1). https://doi.org/10.51298/vmj.v538i1.9343

ESTABLISHMENT OF THE DETECTION OF TERT PROMOTER MUTATIONS IN GLIOMAS BY USING ASO-PCR

Bắc An Lương, Bích Trâm Dương, Anh Vũ Hoàng

Main Article Content

Abstract

Introduction: Gliomas is one of the most frequent types of primary malignant tumors in the central nervous system (CNS), accounting for 75% of all primary malignant brain tumors. The alterations in the TERT promoter have been reported in 70% to 80% of gliomas, suggesting a pivotal role in oncogenesis. The identification of TERT mutations is essential and is currently integrated into gliomas diagnostic procedures. Objective: To study the ASO-SYBR Green PCR procedure for detecting the c.-146C>T mutation in DNA obtained from patients with gliomas. Methods: A cross-sectional descriptive study. Designing specific primers and optimizing the ASO-PCR conditions to detect c.-146C>T mutation. The procedure were validated by the Sanger sequencing. Results: Successully designed primers and optimized the ASO- SYBR Green PCR procedure to detect c.-146C>T mutation. The c.-146C>T mutation results showed 100% concordance with Sanger sequencing results. Conclusion: The successful optimization of the c.-146C>T mutation detection approach by ASO- SYBR Green PCR.

Article Details

Keywords

Glioblastoma, TERT, c.-146C>T, ASO-PCR.

References

1. Yuan Y., Qi C., Maling G., et al. (2016). TERT mutation in glioma: Frequency, prognosis and risk. J Clin Neurosci, 26, 57–62.
2. Janssens G.O., Jansen M.H., Lauwers S.J., et al. (2013). Hypofractionation vs Conventional Radiation Therapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Matched-Cohort Analysis. Int J Radiat Oncol Biol Phys, 85(2), 315–320.
3. Huse J.T. (2015). TERT promoter mutation designates biologically aggressive primary glioblastoma. Neuro-Oncol, 17(1), 5–6.
4. Otsuji K., Sasaki T., Tanabe M., et al. (2021). Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations. Br J Cancer, 124(2), 466–473.
5. Eckel-Passow J.E., Lachance D.H., Molinaro A.M., et al. (2015). Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med, 372(26), 2499–2508.
6. Mosrati M.A., Malmström A., Lysiak M., et al. (2015). TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget, 6(18), 16663–16673.
7. Barbano R., Pasculli B., Coco M., et al. (2015). Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients. Sci Rep, 5.
8. Roma C., Esposito C., Rachiglio A.M., et al. (2013). Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology. BioMed Res Int, 2013.
9. Wang K., Liu T., Ge N., et al. (2014). TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR. Oncotarget, 5(23), 12428–12439.